Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines
Júlia Spinardi, Amit Srivastava
Biomedicines (2023) Vol. 11, Iss. 2, pp. 370-370
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.
Saulesh Kurmangaliyeva, Akzhan M. Madenbayeva, Saltanat T. Urazayeva, et al.
PubMed (2025) Vol. 50, Iss. 2, pp. 61-68
Closed Access | Times Cited: 2
Innate immunity and interferon in SARS-CoV-2 infection outcome
Ram Savan, Michael Gale
Immunity (2023) Vol. 56, Iss. 7, pp. 1443-1450
Open Access | Times Cited: 25
COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
Cureus (2024)
Open Access | Times Cited: 13
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
International Journal of Vaccine Theory Practice and Research (2024) Vol. 3, Iss. 2, pp. 1112-1178
Closed Access | Times Cited: 7
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity
Joshua Tobias, Peter Steinberger, Joy Wilkinson, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 795-795
Open Access | Times Cited: 5
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
Fabrizio Angius, Silvia Puxeddu, S Zaimi, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 17-17
Open Access | Times Cited: 4
Low Neutralization of SARS‐CoV‐2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection
Jianhua Li, Hao Yan, Jiaxuan Li, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Open Access
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China
Siyue Jia, Yuanbao Liu, Qian He, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Vaccination versus natural infection: A review of antibody differentiation techniques
Vaishnavi Mishra, Prashant Gupta, Nandkishor Bankar, et al.
Journal of Research in Medical Sciences (2025) Vol. 30, Iss. 1
Open Access
COVID‐19 in Children With Severe Lung Disease—A Tertiary Center Cohort Study in Denmark
Esben Lægsgaard, Signe Thim, Mette Holm, et al.
Pediatric Pulmonology (2025) Vol. 60, Iss. 4
Open Access
Did COVID-19 surveillance system sensitivity change after Omicron? A retrospective observational study in England
Julii Brainard, Iain Lake, Roger Morbey, et al.
(2025)
Closed Access
COVID-19 vaccination perspectives among patients with Long COVID: A qualitative study
Sarah R. MacEwan, Saurabh Rahurkar, Will L. Tarver, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022
Thomas Althaus, Christopher E. Overton, Isabelle Devaux, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies
Ida Jarlhelt, Laura Pérez‐Alós, Rafael Bayarri‐Olmos, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 5
Open Access | Times Cited: 6
Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5–11 years old children with prior COVID-19
Costanza Di Chiara, Anna Cantarutti, Maria Raffaella Petrara, et al.
Vaccine (2023) Vol. 42, Iss. 2, pp. 263-270
Open Access | Times Cited: 6
Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study
Alessia Raineri, Thomas Radtke, Sonja Rueegg, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 5
To be remembered: B cell memory response against SARS‐CoV‐2 and its variants in vaccinated and unvaccinated individuals
Nafees Ahmed, Atharv Athavale, Ankita Tripathi, et al.
Scandinavian Journal of Immunology (2023) Vol. 99, Iss. 2
Open Access | Times Cited: 5
A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study
Nicola Serra, Maria Andriolo, Ignazio Butera, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1136-1136
Open Access | Times Cited: 4
Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants
Sovan Samanta, Jhimli Banerjee, Aparna Das, et al.
Current Microbiology (2024) Vol. 81, Iss. 3
Closed Access | Times Cited: 1
Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing
Theodora U. J. Bruun, Jonathan Do, Payton A. Weidenbacher, et al.
ACS Central Science (2024) Vol. 10, Iss. 10, pp. 1871-1884
Open Access | Times Cited: 1
Global COVID-19 vaccination in infants and children: Effectiveness, safety, and challenges
Watsamon Jantarabenjakul, Napaporn Chantasrisawad, Rapisa Nantanee, et al.
Asian Pacific Journal of Allergy and Immunology (2023)
Open Access | Times Cited: 3
Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model
Wongyeong Choi, Eunha Shim
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 2
Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination
Christine Durier, Läétitia Ninove, Sylvie van der Werf, et al.
Infectious Diseases Now (2024) Vol. 54, Iss. 5, pp. 104886-104886
Open Access
SARS-CoV-2 immunity and reasons for non-vaccination among healthcare workers from eastern and northern Switzerland: results from a nested multicentre cross-sectional study
Selina Albrecht, Fabian Grässli, Alexia Cusini, et al.
Schweizerische medizinische Wochenschrift (2024) Vol. 154, Iss. 4, pp. 3734-3734
Open Access
Engineering a SARS-CoV-2 vaccine targeting the RBD cryptic-face via immunofocusing
Theodora U. J. Bruun, Jonathan Do, Payton A. Weidenbacher, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top